Stochastic modelling of tyrosine kinase inhibitor rotation therapy in chronic myeloid leukaemia
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Stochastic modelling of tyrosine kinase inhibitor rotation therapy in chronic myeloid leukaemia
Authors
Keywords
-
Journal
BMC CANCER
Volume 19, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-05-28
DOI
10.1186/s12885-019-5690-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
- (2018) Pierre Laneuville CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy
- (2017) Leanne G. Ahronian et al. Genome Medicine
- Uncovering the molecular and physiological processes of anticancer leads binding human serum albumin: A physical insight into drug efficacy
- (2017) Chuanbo Liu et al. PLoS One
- Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia
- (2016) Gabriele Gugliotta et al. AMERICAN JOURNAL OF HEMATOLOGY
- Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response
- (2016) Francisco Cervantes et al. ANNALS OF HEMATOLOGY
- Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients
- (2016) S Soverini et al. LEUKEMIA
- Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells
- (2016) Sheela A. Abraham et al. NATURE
- Drug resistance in cancer: molecular evolution and compensatory proliferation
- (2016) Ran Friedman Oncotarget
- Predictive computational modeling to define effective treatment strategies for bone metastatic prostate cancer
- (2016) Leah M. Cook et al. Scientific Reports
- Quantifying the Landscape for Development and Cancer from a Core Cancer Stem Cell Circuit
- (2015) C. Li et al. CANCER RESEARCH
- S100A4 and its role in metastasis – simulations of knockout and amplification of epithelial growth factor receptor and matrix metalloproteinases
- (2015) Antoine Buetti-Dinh et al. Molecular BioSystems
- Fate of a mutation in a fluctuating environment
- (2015) Ivana Cvijović et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
- (2014) Matthew S. Zabriskie et al. CANCER CELL
- Ponatinib: A Review of Its Use in Adults with Chronic Myeloid Leukaemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia
- (2014) Sheridan M. Hoy DRUGS
- Molecular modelling and simulations in cancer research
- (2013) Ran Friedman et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Evolutionary dynamics of cancer in response to targeted combination therapy
- (2013) Ivana Bozic et al. eLife
- Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors
- (2012) Sara Redaelli et al. AMERICAN JOURNAL OF HEMATOLOGY
- BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships
- (2012) J. S. Khorashad et al. BLOOD
- Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer
- (2012) Robert C. Doebele et al. CLINICAL CANCER RESEARCH
- A branching process model of ovarian cancer
- (2012) Kaveh Danesh et al. JOURNAL OF THEORETICAL BIOLOGY
- Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
- (2012) B Hanfstein et al. LEUKEMIA
- Choosing the Best Second-Line Tyrosine Kinase Inhibitor in Imatinib-Resistant Chronic Myeloid Leukemia Patients Harboring Bcr-Abl Kinase Domain Mutations: How Reliable Is the IC50?
- (2011) S. Soverini et al. ONCOLOGIST
- Fitness Conferred by BCR-ABL Kinase Domain Mutations Determines the Risk of Pre-Existing Resistance in Chronic Myeloid Leukemia
- (2011) Kevin Leder et al. PLoS One
- Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations
- (2009) E. Jabbour et al. BLOOD
- Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors
- (2009) G. D. Demetri et al. CLINICAL CANCER RESEARCH
- Evolution of resistance to anti-cancer therapy during general dosing schedules
- (2009) Jasmine Foo et al. JOURNAL OF THEORETICAL BIOLOGY
- Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia
- (2008) Neil P. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Commentary: Novel Therapies for Cancer: Why Dirty Might Be Better
- (2008) T. Fojo ONCOLOGIST
- Multiple mutant clones in blood rarely coexist
- (2008) David Dingli et al. PHYSICAL REVIEW E
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now